Stay up-to-date with the latest developments in securities law through access to both news and all statutes and regulations. Find relevant corporate filings through a searchable EDGAR database. And...
Investors who bought membership and ownership interests in venture capital groups that purchased Theranos stock can’t bring a class suit against the company, a federal magistrate judge said.
The indirect investors can’t sue Theranos Inc. as a class because five of their six claims lack common issues that predominate over members’ individual issues, according to a May 31 U.S. District Court for the Northern District of California opinion. The investors also sued Theranos CEO Elizabeth Holmes and former chief operating officer Ramesh “Sunny” Balwani.
Theranos is “pleased” with the ruling because it moves the company “a step closer to resolving its outstanding legal issues,” Michael Mugmon, a Wilmer Cutler Pickering Hale and Dorr LLP partner who represented the company, told Bloomberg Law. Cooley LLP, representing Holmes, didn’t have a comment. The other parties’ attorneys didn’t immediately respond to requests for comment.
Investors sued after reports surfaced alleging that Theranos, Holmes, and Balwani lied about the company’s “revolutionary” blood test product in a publicity campaign aimed at investors, according to the November 2016 complaint. The company’s product didn’t work, leading to the company’s collapse, the complaint said.
The Securities and Exchange Commission in March settled securities fraud allegations with Theranos and Holmes, but its case against Balwani is ongoing. Holmes agreed to give up majority control and reduce her equity in the company, the SEC said.
One of the requirements for class certification is that the class members’ common issues predominate over their individual issues. Five of the investors’ six claims involve some element of reliance, making those claims more about members’ individual issues, U.S. Magistrate Judge Nathanael M. Cousins said. The investors can’t get a presumption of reliance because they didn’t show all investors relied on the publicity campaign, according to the court. Additionally, the market for Theranos stock was too inefficient for the fraud-on-the-market theory of reliance to apply, the court said.
Common issues predominate with respect to the investors’ sixth claim, which alleges market manipulation, the court said. However, the investors still didn’t show that a class action was the superior process for resolving their claims, the opinion said. Instead, “the marginal benefits of certifying this narrow class do not outweigh the class’s overall weaknesses,” the court said. The would-be class members still have the option of bringing their claims against Theranos individually.
Davis Wright Tremaine LLP and Ross Aronstam Moritz LLP represented Balwani. Attorneys with Robbins Geller Rudman and Dowd LLP and Hagens Berman Sobol Shapiro LLP represented the investors.
The case is Colman v. Theranos Inc. , 2018 BL 194946, N.D. Cal., No. 16-cv-06822-NC, class certification denied 5/31/18 .
To contact the reporter on this story: Jennifer Bennett in Washington at email@example.com
To contact the editor responsible for this story: Seth Stern at firstname.lastname@example.org
Copyright © 2018 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)